Business
MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results
MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results Canada ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n \n \n \n MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n May 12, 2022\n \n /CNW/ -\n \n MediPharm Labs Corp.\n \n (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (\"MediPharm\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022.\n \n \n \n \n \n \n \n \n \n MediPharm's executive management team will also host a conference call and audio webcast on Monday, May 16, 2022, at 8:30 a.m. eastern time to discuss the Company's financial results and outlook.\n \n \n \n Audio Conference Call Dial in Details:\n \n \n \n Toll-free number: +1 (888) 330-2379 / International number: +1 (240) 789-2714 / Conference ID: 4921762\n \n \n Participants are asked to dial in approximately 15 minutes before the start of the call.\n \n \n \n Audio Webcast:\n \n \n \n An audio webcast will be available in the Events section of the MediPharm website\n \n https://www.medipharmlabs.com/investors\n \n or by visiting the following link\n \n \n here\n \n \n .\n \n \n For those who are unable to participate on the live conference call or webcast, a replay will be available approximately one hour after completion of the call.\n \n \n \n About MediPharm Labs Corp.\n \n \n \n Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced ...